Showing results (21-30 of 79) with videos related to

Sort By:
Pageof 8
Cancer Science|January 24, 2024
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th editionHideaki Bando, Kyoko Yamaguchi, Seiichiro Mitani, et al.
Carcinogenesis|October 3, 2017
Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancerYuta Adachi, Kazuyoshi Watanabe, Kenji Kita, et al.
Cancer Chemotherapy and Pharmacology|April 22, 2005
Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR)Hiromichi Ebi, Yasushi Sigeoka, Toshiaki Saeki, et al.
Carcinogenesis|July 2, 2019
The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesisMohamed I Saad, Louise McLeod, Liang Yu, et al.
Investigational New Drugs|August 29, 2020
Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary reportAkimitsu Maeda, Kei Irie, Naoya Hashimoto, et al.
Cancer Research|July 17, 2004
Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell linesTaku Nakagawa, Yoji Hayashita, Ken Maeno, et al.
American Journal of Clinical Pathology|May 11, 2023
Diagnostic utility of DNA integrity number as an indicator of sufficient DNA quality in next-generation sequencing-based genomic profilingKaho Hiramatsu, Chiaki Matsuda, Katsuhiro Masago, et al.
Cancer Science|July 16, 2020
Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th editionHiromichi Ebi, Hideaki Bando, Hiroya Taniguchi, et al.
Oncotarget|December 31, 2015
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cellsShigeki Nanjo, Hiromichi Ebi, Sachiko Arai, et al.
Cancer Science|March 25, 2015
Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patientsHiroya Taniguchi, Kentaro Yamazaki, Takayuki Yoshino, et al.
Pageof 8